In rats, a new therapy with the blockade of TNF-α has two direct consequences: it blunts the development of the hyperdynamic circulation and reduces portal pressure in a model of portal hypertension [13], and reduces the frequency of BT episodes in model of cirrhosis [14]. Here, TNF is linked to portal hypertension.